Published in:
Open Access
01-12-2016 | Research article
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
Authors:
Jieyi Wang, Liliane Goetsch, Lora Tucker, Qian Zhang, Alexandra Gonzalez, Kedar S. Vaidya, Anatol Oleksijew, Erwin Boghaert, Minghao Song, Irina Sokolova, Ekaterina Pestova, Mark Anderson, William N. Pappano, Peter Ansell, Anahita Bhathena, Louie Naumovski, Nathalie Corvaia, Edward B. Reilly
Published in:
BMC Cancer
|
Issue 1/2016
Login to get access
Abstract
Background
c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by the MET proto-oncogene. Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is associated with poor clinical outcome in multiple malignancies underscoring the importance of c-Met signaling in cancer progression. Several c-Met inhibitors have advanced to the clinic; however, the development of inhibitory c-Met-directed therapeutic antibodies has been hampered by inherent agonistic activity.
Method
We generated and tested a bivalent anti-c-Met monoclonal antibody ABT-700 in vitro for binding potency and antagonistic activity and in vivo for antitumor efficacy in human tumor xenografts. Human cancer cell lines and gastric cancer tissue microarrays were examined for MET amplification by fluorescence in situ hybridization (FISH).
Results
ABT-700 exhibits a distinctive ability to block both HGF-independent constitutive c-Met signaling and HGF-dependent activation of c-Met. Cancer cells addicted to the constitutively activated c-Met signaling driven by MET amplification undergo apoptosis upon exposure to ABT-700. ABT-700 induces tumor regression and tumor growth delay in preclinical tumor models of gastric and lung cancers harboring amplified MET. ABT-700 in combination with chemotherapeutics also shows additive antitumor effect. Amplification of MET in human cancer tissues can be identified by FISH.
Conclusions
The preclinical attributes of ABT-700 in blocking c-Met signaling, inducing apoptosis and suppressing tumor growth in cancers with amplified MET provide rationale for examining its potential clinical utility for the treatment of cancers harboring MET amplification.